Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of romosozumab vs bisphosphonates in pediatric osteogenesis imperfecta
jRCT2061230103Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in osteogenesis imperfecta (OI) comparing Romosozumab with Standard-of-care bisphosphonate (2 arms). Primary endpoints: Number of clinical fractures at 12 months, Number of any fractures at 12 months and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on jRCT2061230103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230103.